HopeStage
Back to all studies
CompletedNCT01149655

Aripiprazole for Adolescents With Schizophrenia

About this titleRead the official source — NCT01149655

This study evaluated the safety and effectiveness of Aripiprazole for people with schizophrenia.

Medication studyAges 13–17Multiple countries
The study in practice

Understand this study

What did researchers investigate?

This study evaluated the safety and effectiveness of Aripiprazole for people with schizophrenia.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 13 years to 17 years. Other eligibility criteria applied.

Listed locations
Downy and 51 more locationsSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateJuly 2011
Recruitment status
Completed
Enrollment listed in the registry
252
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States, India, Malaysia, ...
Age range
From 13 Years to 17 Years
Official registry ID
NCT01149655
Official title
Show the full official title

A Long-Term Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aripiprazole (OPC 14597) as Maintenance Treatment in Adolescent Patients With Schizophrenia

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Downy, United States · Glendale, United States · Miami, United States

48 more locations
  • Miami Springs, United States
  • Atlanta, United States
  • Bloomfield Hills, United States
  • Chapel Hill, United States
  • Bothell, United States
  • Vijayawada, India
  • Visakhapatnam, India
  • Raipur, India
  • Maninagar, Ahmedabad, India
  • Chhatrapati Sambhajinagar, India
  • Wardha, India
  • Chennai, India
  • Madurai, India
  • Lucknow, India
  • Varanasi, India
  • Guntur, India
  • Kuala Lumpur, Malaysia
  • Ipoh, Malaysia
  • Batu Caves, Malaysia
  • Johor Bahru, Malaysia
  • Dasmariñas, Philippines
  • Bajada, Philippines
  • Manila, Philippines
  • Iloilo City, Philippines
  • Mandaluyong, Philippines
  • Cluj-Napoca, Romania
  • Craiova, Romania
  • Timișoara, Romania
  • Bucharest, Romania
  • Iași, Romania
  • Arkhangelsk, Russia
  • Kazan', Russia
  • Lipetsk, Russia
  • Moscow, Russia
  • Nizhny Novgorod, Russia
  • Novosibirsk, Russia
  • Orenburg, Russia
  • Petrozavodsk, Russia
  • Saint Petersburg, Russia
  • Saratov, Russia
  • Tomsk, Russia
  • Tonnelnyi Township, Russia
  • Yaroslavl, Russia
  • Yekaterinburg, Russia
  • Kaohsiung County, Taiwan
  • Taipei, Taiwan
  • Taoyuan County, Taiwan
  • Russia

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What did researchers investigate?

This study evaluated the safety and effectiveness of Aripiprazole for people with schizophrenia.

Who is behind this study?

The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.

Did this study involve medication?

Yes. The study involved medication, including Aripiprazole.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 13 years to 17 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies